Safety and Efficacy of Recombinant Botulinum Toxin Type A for Moderate-to-severe Glabellar Lines: A Multicenter Randomized Controlled Trial
The first rBoNT/A (YY001) in human study demonstrated a favorable safety and tolerability profile (dose-independent) at doses of 10, 20 and 30 U in Chinese subjects with moderate-to-severe glabellar lines. It also showed dose-dependent efficacy benefit.Trial Registration: ChinaDrugTrials.org.cn identifier: CTR20221419.
Authors
- Ping Jiang (ORCID: https://orcid.org/0000-0002-4097-5115)
- Chongyuan Xu
- Z. Q. Hu
- Wu Yang
- Xiaoyun Sun
- Yun Xie
- Nanze Yu
- Xiao Long
- Qingfeng Li
Institutions
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Peking Union Medical College Hospital (CN)
- Shanghai Ninth People's Hospital (CN)
- Chongqing Medical and Pharmaceutical College (CN)
- Southern Medical University (CN)
Publication Details
- Journal
- Plastic & Reconstructive Surgery
- Published
- 2026-02-23
- DOI
- https://doi.org/10.1097/prs.0000000000012960
- Primary Topic
- Botulinum Toxin and Related Neurological Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00